The EC has authorised SPRAVATO (esketamine) nasal spray in combination with a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved the supplemental new drug application (sNDA) for Spravato (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved Spravato (esketamine) nasal spray,...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the FDA has approved Spravato (esketamine) CIII nasal spray for...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and...
THe National Institute for Health and Care Excellence (NICE) has rejected Spravato (esketamine) from Janssen for a second time and the company may be obliged to reduce its price further.
In two pivotal Phase 3 trials, SPRAVATO® combined with comprehensive standard of care achieved statistically significant rapid reduction of depressive symptoms...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive results from two pivotal Phase III clinical studies (ASPIRE I...
An open-label, international study published in the New England Journal of Medicine found that patients receiving Spravato (esketamine) CIII nasal spray for treatment-resistant depression (TRD) were 1.54 times as likely to reach remission after eight weeks than those treated with quetiapine extended-release (XR) at Week 8, (27.1% vs. 17.6%, respectively).
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has authorised the expanded use of Spravato (esketamine nasal spray), co-administered with oral antidepressant therapy in adults with a moderate to severe episode of MDD, as acute short term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.